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Abstract
Rationale: High rates of recurrent tuberculosis after successful treatment have been reported from different high burden
settings in Sub-Saharan Africa. However, little is known about the rate of smear-positive tuberculosis after treatment default.
In particular, it is not known whether or not treatment defaulters continue to be or become again smear-positive and thus
pose a potential for transmission of infection to others.
Objective: To investigate, in a high tuberculosis burden setting, the rate of re-treatment for smear-positive tuberculosis
among cases defaulting from standardized treatment compared to successfully treated cases.
Methods: Retrospective cohort study among smear-positive tuberculosis cases treated between 1996 and 2008 in two
urban communities in Cape Town, South Africa. Episodes of re-treatment for smear-positive tuberculosis were ascertained
via probabilistic record linkage. Survival analysis and Poisson regression were used to compare the rate of smear-positive
tuberculosis after treatment default to that after successful treatment.
Results: A total of 2,136 smear-positive tuberculosis cases were included in the study. After treatment default, the rate of re-
treatment for smear-positive tuberculosis was 6.86 (95% confidence interval [CI]: 5.59–8.41) per 100 person-years compared
to 2.09 (95% CI: 1.81–2.41) after cure (adjusted Hazard Ratio [aHR]: 3.97; 95% CI: 3.00–5.26). Among defaulters, the rate was
inversely associated with treatment duration and sputum conversion prior to defaulting. Smear grade at start of the index
treatment episode (Smear3+: aHR 1.61; 95%CI 1.11–2.33) was independently associated with smear-positive tuberculosis re-
treatment, regardless of treatment outcome.
Conclusions: In this high-burden setting, there is a high rate of subsequent smear-positive tuberculosis after treatment
default. Treatment defaulters are therefore likely to contribute to the pool of infectious source cases in the community. Our
findings underscore the importance of preventing treatment default, as a means of successful tuberculosis control in high-
burden settings.
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Introduction
Amajor principle in tuberculosis control is the necessity to ensure
that patients adhere to a full course of treatment. At least six months
anti-tuberculosismultidrugchemotherapy is required toachievecure
in smear-positive tuberculosis patients with initially drug-susceptible
disease [1]. Shorter treatment regimens result in high rates of disease
recurrence within 24 months after treatment [2–4].
Adherence to a full course of treatment is therefore expected not
only to prevent disease recurrence, but also to contribute to
a reduction in tuberculosis burden at population level [5]. The
latter is based on the assumption that patients not successfully
treated remain contagious or experience recurrent disease and
contribute to an increased burden of disease and transmission of
tuberculosis within the community.
Non-adherence to a full course of anti-tuberculosis treatment
is usually termed ‘treatment default’, defined as interruption of
treatment for at least two consecutive months. Risk factors for
treatment default such as lack of knowledge and family support,
distance between home and health care facility, and drug side
effects have been widely studied [6–8], but little is known about
the fate of patients after defaulting from anti-tuberculosis
treatment. It is not known whether or not treatment defaulters
continue or return again sputum smear-positive and thus pose
a potential for transmission of infection to others.
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While treatment defaulters could be specifically targeted by
interventions to prevent default, to retrieve those who have
defaulted and to prevent subsequent recurrence of disease [9],
such interventions require scarce resources that must be rationed
properly based on an assessment of the size of the problem and the
ease of its solution.
This study was conducted in a setting with a high tuberculosis
burden in South Africa. High rates of recurrent tuberculosis after
successful treatment have been reported from this and other
settings in Sub-Saharan Africa. Exogenous re-infection rather than
relapse seems to be the major underlying cause of recurrence in
successfully treated cases [10–12], with the proportion of re-
infection increasing with background tuberculosis incidence [13],
and with human immunodeficiency virus (HIV) co-infection being
an important risk factor [14–16].
In the context of frequent tuberculosis re-infection, little is
known about the significance of treatment default as a risk factor
for smear-positive tuberculosis.
The objective of this study was to investigate the rate of re-
treatment for smear-positive tuberculosis, after defaulting from an
initial treatment episode. We hypothesised that in a setting with
a high tuberculosis burden, sputum smear-positive tuberculosis
cases who default from treatment are more likely to return for
treatment with smear-positive disease compared to those who
successfully complete their treatment. We further aimed to
investigate whether treatment duration and sputum conversion




Two adjacent urban communities covering an area of 3.4 km2
with 36,000 inhabitants of low socio-economic status and a high-
burden of tuberculosis in metropolitan Cape Town, South Africa
[17]. The DOTS strategy [18] was introduced in 1996 to both
communities where two primary health-care clinics provide
treatment and routinely record and report cases started on
treatment. Treatment regimens were in accordance with standards
for South Africa [19]: For cases never previously treated (new
cases), this was six months of daily isoniazid and rifampicin
supplemented by daily pyrazinamide and ethambutol for the first
two months, extended for a further month if the sputum smear was
positive at the end of two months. Treatment for re-treatment
cases consisted of daily isoniazid, rifampicin and ethambutol for
eight months supplemented with daily pyrazinamide and strepto-
mycin in the first three months.
Treatment outcomes were documented by local health care staff
according to standard definitions [19]. This included cure, for
patients who were smear-positive at initiation of treatment and
smear-negative at, or one month prior, to the completion of
treatment and also on at least one previous occasion, and
treatment completed, for patients who had completed treatment
Figure 1. Overview of smear-positive tuberculosis cases included in and excluded from the study.
doi:10.1371/journal.pone.0045724.g001
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but without proof of cure due to smear results not available on at
least two occasions prior to the completion of treatment. The term
‘treatment success’ includes both, cure and treatment completed.
The outcome of treatment default was recorded for a tuberculosis
case whose treatment was interrupted for more than two
consecutive months before the end of the treatment period.
Health care staff members were advised to record the date of
treatment default as the last date at which the patient picked up
medication before defaulting, and, in the case of interruption for
less than two months, to trace the patient and to prolong treatment
in order to compensate for missed doses.
Data Sources
Routine program data entered by local health care staff from
both clinics into paper-based tuberculosis treatment registers for
the years 1996 to 2008 were captured in an electronic database.
Missing values for treatment end date and treatment outcome
were ascertained as follows: If no end date (default date) was
documented in the treatment register, the patient file was reviewed
and the last day at which the patient was documented to have
taken up medication was accepted as the end date. If no treatment
outcome was documented in the register, patient files were
reviewed and the documented treatment outcome was updated in
the database.
Study Design
A retrospective cohort study was conducted, comparing sputum
smear-positive tuberculosis cases who successfully completed
treatment to those who defaulted from treatment between 1996
and 2008. From the database, we selected all episodes of treatment
with a documented smear-positive sputum result at start of
treatment and a treatment outcome of either cure, treatment
completed or treatment default. ‘Sputum smear-positive’ was
defined by at least one sputum sample documented smear-positive
for acid-fast bacilli by fluorescence microscopy. Episodes of
second-line treatment, episodes of treatment for smear-negative
tuberculosis, episodes with treatment outcomes other than success
or default and those without a treatment outcome documented,
were not included in the study. We further excluded episodes with
a treatment end date after 31st October 2008, in order to allow for
sufficient time to re-treatment (see below).
All treatment episodes included in the study were defined as
index episodes. An episode of re-treatment for smear-positive
tuberculosis (study outcome) was defined as any subsequent
episode of treatment for documented smear-positive tuberculosis
Figure 2. Ascertainment of subsequent episodes of re-treatment via record linkage and manual review for the study.
doi:10.1371/journal.pone.0045724.g002
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recorded for the same individual person, with a minimum time of
two months between the end date of the index episode and the
record date of the re-treatment episode.
Ascertainment of Smear-positive Tuberculosis Re-
treatment
We used Registry PlusTM/Link-Plus [20] probabilistic record
linkage software to identify episodes of re-treatment for smear-
positive tuberculosis recorded in the treatment registers. The
software matches records on the basis of matching variables and
assigns a probability score for a true (individual) match of two
independent records. Each index treatment episode included in
the study was screened for matches with any subsequent treatment
episode recorded for the same individual person in the treatment
registers. First and family name (case-sensitive), sex and year of
birth were chosen as matching variables.
Matches of treatment episodes identified from the record
linkage were initially reviewed and classified on the basis of
concordance of the matching variables into perfect matches,
highly probable matches and probable matches: A ‘perfect match’
was defined by 100% concordance of each, first and surname, sex
and year of birth. ‘Highly probable matches’ had minor spelling
differences in first- or surname and 100% concordance of both,
sex and year of birth. ‘Probable matches’ had 100% concordance
or minor spelling differences of first- and surname and 100%
concordance of either sex or year of birth but discordance or
Table 1. Univariable analysis of index episode risk factors for subsequent smear-positive tuberculosis re-treatment (N= 2,136).
Total re-treatment
cases PY Rate (per 100 PY)
Crude hazard-ratio
(95% CI) P-value
Overall 291 10844 2.68 (2.39–3.01)
Treatment outcome ,0.001
Cured 185 8863 2.09 (1.81–2.41) 1
Completed 14 640 2.19 (1.29–3.69) 1.05 (0.61–1.80)
Defaulted 92 1341 6.86 (5.59–8.41) 3.29 (2.56–4.22)
Sex 0.005
Female 93 4352 2.14 (1.74–2.62) 1
Male 198 6492 3.05 (2.65–3.51) 1.43 (1.12–1.83)
Age 0.002
0–18 30 758 3.96 (2.77–5.66) 1
19–39 193 6646 2.90 (2.52–3.34) 0.73 (0.50–1.08)
40+ 68 3430 1.98 (1.56–2.51) 0.50 (0.33–0.77)
Patient category 0.03
New 181 7384 2.45 (2.12–2.84) 1
Re-treatment 110 3424 3.21 (2.67–3.87) 1.31 (1.03–1.66)
HIV status 0.10
negative 111 3542 3.13 (2.60–3.77) 1
positive 12 383 3.13 (1.78–5.52) 1.00 (0.55–1.81)
unknown 168 6919 2.43 (2.09–2.82) 0.77 (0.61–0.98)
Smear grade* 0.03{
Smear 1+ 35 1588 2.20 (1.58–3.07) 1
Smear 2+ 48 1576 3.05 (2.30–4.04) 1.38 (0.89–2.14)
Smear 3+ 154 4641 3.32 (2.83–3.89) 1.51 (1.04–2.17)
Smear conversion (month 2) 0.03
Yes (smear-negative) 189 8297 2.28 (1.98–2.63) 1
No (smear-positive) 60 1899 3.16 (2.45–4.07) 1.39 (1.04–1.85)
Treatment duration ,0.001
.8 months 53 1858 2.85 (2.18–11.32) 1.47 (1.06–2.03)
6–8 months 120 6177 1.94 (1.62–2.32) 1
4 – ,6 months 88 2431 3.62 (2.94. –4.46) 1.86 (1.42–2.45)
,4 months 30 379 7.92 (5.54–12.23) 4.08 (2.73–6.08)
PY = Person-years.
CI = Confidence Interval.
*Smear grade at start of treatment:
Smear 3+: Any of the two initial smears was 3+,i.e. .10 acid-fast bacilli (AFB) per 1 high-power field (HPF).
Smear 2+: Any of the two initial smears was 2+,i.e. 1–10 AFB per 1 HPF, but none of them was 3+.
Smear 1+: Any of the two initial smears was 1+,i.e. 10–99 AFB per 100 HPF, but none of them was 2+ or 3+.
{Test for trend.
doi:10.1371/journal.pone.0045724.t001
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a missing value of the remainder of the two. Matches identified by
the software that did not meet these criteria were discarded.
In order to ensure that index and re-treatment episode belonged
to the same individual person, all perfect, highly-probable and
probable matches underwent careful manual review using the
Table 2. Multivariable analysis of index episode risk factors for subsequent smear-positive tuberculosis re-treatment (N= 1,733).
Total re-treatment cases PY Rate (per 100 PY) Crude hazard-ratio* (95% CI) P-value
Treatment outcome ,0.001
Cured 185 8863 2.09 (1.81–2.41) 1
Completed 14 640 2.19 (1.29–3.69) 1.08 (0.58–2.00)
Defaulted 92 1341 6.86 (5.59–8.41) 3.97 (3.00–5.26)
Smear grade{ 0.03{
Smear 1+ 35 1588 2.20 (1.58–3.07) 1
Smear 2+ 48 1576 3.05 (2.30–4.04) 1.43 (0.93–2.22)
Smear 3+ 154 4641 3.32 (2.83–3.89) 1.61 (1.11–2.33)
Age 0.003
0–18 30 758 3.96 (2.77–5.66) 1
19–39 193 6646 2.90 (2.52–3.34) 0.50 (0.32–0.78)
40+ 68 3430 1.98 (1.56–2.51) 0.40 (0.25–0.65)
PY = Person-years.
CI = Confidence Interval.
*Adjusted for the other factors shown in the table.
{Smear grade at start of treatment:
Smear 3+: Any of the two initial smears was 3+, i.e. .10 acid-fast bacilli (AFB) per 1 high-power field (HPF).
Smear 2+: Any of the two initial smears was 2+, i.e. 1–10 AFB per 1 HPF, but none of them was 3+.
Smear 1+: Any of the two initial smears was 1+, i.e. 10–99 AFB per 100 HPF, but none of them was 2+ or 3+.
{Test for trend.
doi:10.1371/journal.pone.0045724.t002
Figure 3. Kaplan Meier failure estimates of re-treatment for smear-positive tuberculosis by index episode sputum smear grading
and treatment outcome.
doi:10.1371/journal.pone.0045724.g003
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original paper-based treatment registers and, if necessary, patient
folders as a reference. In line with the study definition for episodes
of re-treatment for smear-positive tuberculosis, matches were
excluded if the time period between the end date of the index
episode and the record date of the re-treatment episode was
shorter than two months.
Data Analysis
STATATM 10.1 statistical application (Stata Corp, College
Station, TX, USA) was used for data analysis. Survival analysis
and Poisson regression were used to determine rates of re-
treatment for smear-positive tuberculosis after treatment default
vs. after cure/completion. Cases entered the study on the date
when they successfully completed or defaulted from the index
treatment episode and were censored on the date when the first re-
treatment episode (smear-positive) was recorded in the registers or
else at the end of the study period. A multivariable regression
model was developed using a step-wise forward technique: co-
factors documented at the index episode were considered if they
reached P,0.10 significance at univariable regression and resulted
in a change of +/20.1 Rate Ratio for the principal determinant
under study. Among treatment defaulters, sub-group analysis was
conducted, taking into consideration treatment duration, and
sputum conversion prior to defaulting, as documented at the end
of the intensive phase of treatment (month 2–3).
Ethics Statement
Permission to access the program data for research has been
granted by the City of Cape Town (research ID=10142), the
custodian of the data. The study was approved by the
Figure 4. Kaplan Meier failure estimates of smear-positive re-treatment after treatment default, stratified by smear conversion
prior to defaulting (adjusted for time to default).
doi:10.1371/journal.pone.0045724.g004
Table 3. Treatment outcomes at re-treatment stratified by index episode treatment outcome (N= 291 re-treatment cases).
Treatment outcome, re-treatment episode
Total
Cured/
Completed Failed Died Defaulted Transfer out Unknown
Treatment outcome, index
episode
Cured/Completed 199 (100.0%) 152 (76.4%) 12 (6.0%) 8 (4.0%) 17 (8.5%) 2 (1.0%) 8 (4.0%)
Treatment default 92 (100.0%) 49 (53.3%) 3 (3.3%) 2 (2.2%) 34 (37.0%) 3 (3.3%) 1 (1.1%)
Total 291 (100.0%) 201 (69.1%) 15 (5.2%) 10 (3.4%) 51 (17.5%) 5 (1.7%) 9 (3.1%)
doi:10.1371/journal.pone.0045724.t003
Smear-Positive Tuberculosis after Default
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Committee for Human Research, Faculty of Health Sciences,
Stellenbosch University (N09/05/144 and amendments 1 and 3)
and also by the Ethics Advisory Group of the International
Union Against Tuberculosis and Lung Disease. This was
a retrospective analysis of routine data and therefore we
requested and were granted a waiver of individual informed
consent from the ethics committee. The use of a unique subject
ID ensured anonymous analysis. Only the senior data staff had
access to personal identifiers which were removed after the
record linkage process.
Results
A total of 2,521 tuberculosis cases with an episode of first-line
treatment for smear-positive tuberculosis were recorded in the
treatment registers 1996–2008. Of these, 2,136 were included in
the study, 1,743 with documented cure, 126 with treatment
completion and 267 with treatment default. A breakdown of cases
included and excluded is shown in Figure 1.
Of all cases included, 1,274 (59.6%) were male, median age was
34 years, and 1,065 (49.9%) had an HIV test result documented,
110 (10.3%) of whom were HIV positive.
Re-treatment for Smear-positive Tuberculosis
For 291 (13.6%) of the 2,136 smear-positive cases included in
the study, an episode of re-treatment for smear-positive tubercu-
losis was identified via record linkage and confirmed via manual
review. A detailed overview of the record linkage and manual
review is shown in Figure 2.
Median time between the end date of the index episode and the
record date of the subsequent episode was 17 months. Ninety-two
of the 291 cases with re-treatment for smear-positive tuberculosis
(31.6%) had defaulted at the index treatment episode.
The rate of re-treatment for smear-positive tuberculosis was
2.09 (95% confidence interval [CI]: 1.81–2.41) per 100 person-
years after cure, 2.19 (95%CI: 1.29–3.69) after treatment
completion, and 6.86 (95%CI: 5.59–8.41) after previous treatment
default.
For tuberculosis cases defaulting during the index episode, the
unadjusted Hazard Ratio (HR) of re-treatment was 3.29 (95%CI:
2.56–4.22) using cases with cure as the baseline (Table 1). Sputum
smear grading at start of the index treatment episode (Smear 3+:
HR 1.61; 95%CI: 1.11–2.33) and age ($40 years: HR 0.40;
95%CI: 0.25–0.65) were each independently associated with
smear-positive tuberculosis re-treatment (Table 2). After adjusting
for initial smear grade and age, the HR for smear-positive
tuberculosis re-treatment among defaulters was 3.97 (95%CI:
3.00–5.26).
In cases after treatment default, there was a steep increase in the
cumulative rate of smear-positive tuberculosis within the first two
years. By the end of the second year, 27.9% (95% CI 22.8% –
33.8%) had experienced a re-treatment episode, compared to
5.8% (95%CI: 4.7%–7.0%) of cases after cure. The failure
function for cases after default differed according to smear-grading
at start of treatment (P = 0.04; after treatment success: P = 0.05)
(Figure 3).
Re-treatment Rates by Treatment Duration and Smear
Status Prior to Defaulting
Among the 267 treatment defaulters, 17 (6.4%) defaulted during
the intensive phase of treatment. There was an inverse linear
association between the time to treatment default (i.e. months of
treatment prior to defaulting) and the rate of re-treatment (aHR:
0.87 [95%CI: 0.78–0.97] per one month of treatment; P= 0.01).
Of the treatment defaulters, the sputum smear result at the end
of the intensive phase of treatment was negative in 149 (55.8%),
positive in 43 (16.1%) and not documented in 75 (28.1%). The
rate of smear-positive tuberculosis re-treatment was 5.81 (95% CI:
4.34–7.78) per 100 person-years among defaulters with documen-
ted sputum conversion prior to defaulting, 6.07 (95% CI: 3.66–
10.07) with documented positive sputum smear result at follow-up,
and 10.00 (95% CI: 7.07–14.14) among treatment defaulters
without documented follow-up sputum smear-result. Figure 4
shows the failure function for smear-positive tuberculosis re-
treatment by sputum smear status prior to defaulting, adjusted for
time to treatment default.
Treatment Outcomes at Re-treatment
Thirty-four (37.0%) of the 92 re-treatment tuberculosis cases who
defaulted from treatment at the index episode, defaulted again from
re-treatment, compared to 17 (8.5%) of 199 re-treatment cases
defaulting after previous cure or treatment completion (Table 3).
Discussion
This studydemonstrates for the first timethe substantiallyhighrate
of smear-positive tuberculosis associated with previous treatment
default.Treatment default remains amajor risk factor for subsequent
smear-positive tuberculosis, even in settings where tuberculosis
recurrence due to re-infection is generally common.
The rates of smear-positive tuberculosis presented here are
based on treatment records and likely underestimate the true rates
of smear-positive tuberculosis after cure, treatment completion
and default, because some of the tuberculosis cases might not have
returned for treatment or they might have sought treatment
elsewhere, and because the population at risk in this study includes
those who might have moved or died.
The differences in the rates of smear-positive tuberculosis
after treatment default vs. after success are due to the strikingly
higher rates within the first two years in those defaulting from
treatment. Our results suggest that tuberculosis had been
initially contained in the majority of treatment defaulters, i.e.
those with longer time to default and with documented smear
conversion, and worsened very soon after stopping the
treatment. Cases defaulting earlier from treatment and those
who continue smear-positive most likely continue to suffer from
active disease resulting in high rates of re-treatment within the
first two years after defaulting. Absence of smear examination
recorded at the end of the initial phase may be a marker of
irregular clinic attendance prior to default.
Treatment default is widely considered a risk factor for disease
re-activation, but very few studies have looked at rates of
tuberculosis after treatment default. A study on re-infection
among successfully treated cases in the same communities 1993–
1998 documented the frequency of culture confirmed tuberculosis
in a sample of previous treatment defaulters for whom strain type
information was available, similar to those we found [11]. A study
conducted by Vree et al. in rural Vietnam found of 33 treatment
defaulters with known outcome, seven had died; only one was
found to be culture positive and 23 smear- and culture negative
[21].
The rate of recurrent smear-positive tuberculosis after treatment
success corresponds well with previous findings from the Western
Cape Province [11] and with reports from late phase clinical trials
with a rate of 5.0% at 24 months of follow-up in 282 cases treated
in routine public services in Benin, Guinea, Tanzania, Mozambi-
que, Nepal and China, and a rate of 3.8% at 18 months of follow-
Smear-Positive Tuberculosis after Default
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up in 1,103 cases treated in Guinea, Tanzania, Mozambique,
Algeria, Nepal, Vietnam, Bolivia, Colombia and Peru [22,23].
The more constant rate of recurrent episodes after treatment
success suggests that recurrence in this group may be more likely
due to re-infection, as suggested previously [11,12].
The extent to which smear-positive cases after both, previous
default and previous success, maintain the tuberculosis epidemic in
this high-burden community cannot be determined from the
results of this study. Den Boon et al. previously showed in
a prevalence survey conducted in the same setting, that 56% of
previously undetected prevalent smear-positive tuberculosis cases
had a history of previous treatment [24]. These findings along with
the findings of our study support the hypothesis that previously
treated cases contribute considerably to the pool of infectious cases
in the community.
Although the rate of smear-positive tuberculosis among
treatment defaulters is higher, cases after treatment success
account for the vast majority of recurrent smear-positive
tuberculosis in this setting, a finding that is similar to those
reported by Wood et al. in a study using notification data from
Cape Town [25]. This is explained by a higher absolute number of
successfully treated cases, and a rate of recurrence in this group
that is lower in the first two years but constant in the following
years.
We did not find evidence in our study that the rate of smear-
positive recurrent tuberculosis was higher among HIV co-infected
cases. HIV infected individuals may be less likely to be smear-
positive upon recurrence and those living with HIV might be more
likely to die, reducing the ‘person-years at risk’ which would result
in lower rates.
Sputum smear grade at start of treatment was associated with
smear-positive recurrence, independent of the later treatment
outcome – similar to findings reported by Hesseling et al. in
a cohort study from the same community using 24 months follow-
up [26]. Tuberculosis cases with a high initial yield of
mycobacteria might represent those with more severe, i.e.
cavitating, disease [27].
Our study has limitations. We made use of probability record
linkage in order to identify subsequent episodes of treatment
among individuals. Although this method is considered sensitive
[28], we might have failed to detect re-treatment episodes of
smear-positive tuberculosis in some patients, if for instance women
married and changed their surname. Further, the design of our
study did not allow us to capture events of subsequent smear-
positive tuberculosis untreated or treated elsewhere. The ‘popu-
lation at risk’ might have changed according to individuals who
died or who moved away from the area. All these factors would
have led ultimately to an underestimate of the rates of smear-
positive tuberculosis. Rates would have been overestimated if the
linkage of episodes was less specific. However, we tried to exclude
this possibility by using clear definitions of matches and
conducting a careful manual review. We are therefore confident
that the rates presented here were unaffected by matching error.
Residual confounding might have occurred in our study, given
that we were unable to control for other factors known to affect the
risk of tuberculosis recurrence, such as smoking, persistent cavities,
or undetected drug-resistant disease [29–32].
Further, this study is an evaluation of routine health services
based on the information that existed within those services. Such
information might be less accurate than information prospectively
collected as part of a research project. As noted above, the study
did not take into account patients who, for whatever reason, did
not return to the health service.
Conclusions
We show for the first time that in a high-burden setting,
tuberculosis cases defaulting from their treatment are at high risk
of subsequent smear-positive disease. They may thus very likely
experience adverse health effects including chronic pulmonary
impairment [33], death [34], and acquisition of drug-resistance
[35]. Further, they may contribute to the pool of infectious source
cases in the community. Moreover, previous defaulters in this
setting are at high risk of defaulting again from treatment. There is
an urgent need to enhance treatment adherence in order to avoid
these untoward events.
Further research is needed to understand to what extent
treatment defaulters contribute to overall transmission of tuber-
culosis within high-burden communities and whether preventing
default is an efficient means for reducing tuberculosis transmission.
Further, it needs to be determined whether treatment default
contributes to the acquisition and transmission of drug resistance
in high-burden communities.
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